This site is intended only for Australian Healthcare Professionals

Search

Menu

Close

Sign In or RegisterLog Out Our medicinesTherapy areasExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubKnowledge Hub

Menu

Close

About JAKi Experience  JAKi Market Experience XELJANZ Mechanism of Action Efficacy and Safety Clinical Efficacy RA Rapid Data (ACR20) Head-to-Head Noninferiority Data (ACR50) Clinical Efficacy PsA ACR20 Data PASI75 Data Enthesitis and Dactylitis Data Clinical Efficacy UC 8-Week Efficacy Onset of Action Data 52-Week Efficacy OCTAVE Study Design Safety and Tolerability Safety in RA Safety in PsA Safety in UC Safety in ASSafety in JIAClinical Efficacy AS ASAS20/40 Data
Back Pain and Spinal Mobility Data
ASDAS(CRP) Data
Clinical Efficacy JIA
Disease Flare Data
ACR30/50/70 Data
 Dosing and Administration Dosing in RA Dosing Practical Considerations Dosing in PsA Dosing Practical Considerations Dosing in UC Dosing Practical Considerations Dosing in AS
Dosing Practical Considerations Dosing in JIA
Dosing Practical Considerations Resources and Support Resources and Support EventsMaterials Videos
Dosing and administration in JIA1 ​​​​​​​XELJANZ® is the only advanced therapy with 2 oral formulations for JIA: tablets and oral solution1Pack and bottle shown not true to size.
  • The weight-based dose of XELJANZ is administered twice daily in 5 mg tablets (patients ≥40 kg) or a grape-flavored oral solution (weight-based dosing)
  • It is recommended not to initiate dosing in patients with an absolute lymphocyte count (ALC) less than 0.75 x 109 cells/L3
  • Dose interruption may be needed for the management of lymphopaenia, neutropaenia, and anaemia
  • Interrupt use of XELJANZ tablets/XELJANZ Oral Solution if a patient develops a serious infection until the infection is controlled
  • Take XELJANZ tablets/XELJANZ Oral Solution with or without food
  • Administer XELJANZ Oral Solution using the included press-in bottle adapter and oral dosing syringe

Recommended dosage of XELJANZ tablets/XELJANZ Oral Solution in Patients With JIA1​​​​​​​

Patients weighing ≥40 kg treated with 5 mL XELJANZ twice daily XELJANZ Oral Solution may be switched to a XELJANZ 5 mg twice daily tablet. Patients weighing <40 kg cannot be switched from XELJANZ Oral Solution.1

XELJANZ Oral Solution was designed for patients with JIA1​​​​​​​

Explore more Practical considerations for XELJANZ dosing Learn more

ANC=absolute neutrophil count; JIA=juvenile idiopathic arthritis.

Reference:XELJANZ (tofacitinib citrate) Approved Product Information.
Dosing and Administration in JIA SAFETY

See the XELJANZ safety data for JIA

 See safety in JIA EFFICACY

Curious about XELJANZ efficacy in JIA? 

 See JIA data

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

WARNINGS 
XELJANZ should only be used if no suitable treatment alternatives are available in patients: 
  • with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past, long-time smokers) 
  • with malignancy risk factors (e.g. current malignancy or history of malignancy) 
  • who are 65 years of age and older. 

See PI for details, Section 4.4 Special Warnings and Precautions for Use: Mortality; Major Adverse Cardiovascular Events (including Myocardial Infarction); Thrombosis; Malignancy and Lymphoproliferative Disorder (excluding Nonmelanoma Skin Cancer [NMSC]); Skin Cancer and Use in the Elderly. 


Before prescribing, please review full Product Information available here.
 

PBS Information:  Authority required. Refer to PBS Schedule for full authority information.

®Registered Trademark.
PP-XEL-AUS-1434 08/23.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.

 

©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.

 

PP-UNP-AUS-0551 12/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
 
PP-UNP-AUS-0551 12/23.